Bleakley Financial Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bleakley Financial Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$680K	Buy	+11,892	New	+$651K	0.01%	735
2025 Q1	–	Sell	-5,014	Closed	-$330K	–	565
2024 Q4	$330K	Buy	+5,014	New	+$336K	0.01%	763
2024 Q3	–	Sell	-2,548	Closed	-$210K	–	1032
2024 Q2	$210K	Sell	2,548 -410	-14%	-$34.1K	0.01%	881
2024 Q1	$258K	Sell	2,958 -104	-3%	-$9.31K	0.01%	807
2023 Q4	$295K	Buy	3,062 +91	+3%	+$8.05K	0.01%	740
2023 Q3	$263K	Buy	2,971 +228	+8%	+$20.3K	0.01%	721
2023 Q2	$238K	Buy	2,743 +83	+3%	+$7.81K	0.01%	796
2023 Q1	$259K	Sell	2,660 -13,125	-83%	-$1.36M	0.01%	748
2022 Q4	$1.63M	Buy	+15,785	New	+$1.48M	0.06%	295

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Bleakley Financial Group's BMRN Position: Q2 2026 in Review

Bleakley Financial Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 11,892 shares worth $680K. The stake represents 0.01% of the portfolio and ranks #735 among its holdings. This is a return to the name: Bleakley Financial Group previously reported a position in BMRN as recently as Q4 2024.

Bleakley Financial Group first reported a position in BMRN in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.63M in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Bleakley Financial Group held 11,892 shares of BioMarin Pharmaceuticals worth $680K as of Q2 2026.
BioMarin Pharmaceuticals was a new Bleakley Financial Group position in Q2 2026.
BioMarin Pharmaceuticals made up 0.01% of Bleakley Financial Group's portfolio in Q2 2026, its #735 holding.
Bleakley Financial Group first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Bleakley Financial Group's BioMarin Pharmaceuticals position peaked at $1.63M in Q4 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Bleakley Financial Group's 13F filing for Q2 2026, filed 5 Aug 2026.